

**NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE****Health Technology Evaluation****Port Delivery Platform with ranibizumab for treating wet age-related macular degeneration****Final scope****Remit/evaluation objective**

To appraise the clinical and cost effectiveness of Port Delivery Platform with a customised formulation of ranibizumab within its marketing authorisation for treating wet age-related macular degeneration which has responded to anti-VEGF treatment.

**Background**

The macula is the central part of the retina responsible for colour vision and perception of fine detail. Age-related macular degeneration (AMD) is when ageing causes damage to the macula, which can lead to severe visual impairment in the affected eye.

AMD is a common cause of vision loss in people aged over 50 and is associated with the loss of central vision and visual distortion. There are 2 main types of AMD, wet (neovascular) and dry (non-neovascular). Wet AMD usually develops much more quickly than dry AMD and is characterised by the growth of abnormal blood vessels beneath the retina. These new blood vessels are fragile and more likely to haemorrhage, which causes scarring of the macula leading to vision impairment. Wet AMD accounts for around 10% of all cases of AMD and about 60% of advanced (late-stage) cases.<sup>1</sup> In the UK, prevalence of wet AMD is estimated to be 1.2% (2.5% in those aged 65 or above and 6.3% in those aged 80 or above) with an estimated 40,000 new cases of wet AMD in the UK each year.<sup>2</sup>

The NICE guideline on AMD ([NG82](#)) recommends offering intravitreal anti-vascular endothelial growth factor (VEGF) treatment. Anti-VEGF medications that are licensed options for the treatment of wet AMD include ranibizumab (intravitreal injection formulation; [TA155](#)), afibercept ([TA294](#)), brolucizumab ([TA672](#)), faricimab ([TA800](#)), and bevacizumab gamma ([TA1022](#)). Each guidance recommends treatment when:

- the best-corrected visual acuity is between 6/12 and 6/96,
- there is no permanent structural damage to the central fovea,
- the lesion size 12 disc areas or less in greatest linear dimension, and
- there is evidence of recent disease progression.

NG82 also recommends considering anti-VEGF treatment for wet AMD with best-corrected visual acuity of 6/96 or worse if it will benefit the person's overall visual function (for example, if the affected eye is the person's better-seeing eye).

**The technology**

Port Delivery Platform (Contivue, Roche) with a customised formulation of ranibizumab (Susvimo, Roche) does not currently have a marketing authorisation in the UK for the treatment of wet AMD. Ranibizumab as an intravitreal injection has a marketing authorisation in the UK for the treatment of wet AMD. Port Delivery

## Appendix B

Platform with a customised formulation of ranibizumab has been studied in a non-inferiority clinical trial compared with ranibizumab as an intravitreal injection formulation in adults with wet age-related macular degeneration whose disease has responded to anti-VEGF treatment.

<b>Intervention</b>	Port Delivery Platform with a customised formulation of ranibizumab
<b>Population</b>	Adults with wet age-related macular degeneration which has responded to anti-VEGF treatment
<b>Comparators</b>	<ul style="list-style-type: none"><li>• Ranibizumab (intravitreal injection formulation)</li><li>• Aflibercept</li><li>• Bevacizumab gamma</li><li>• Brolucizumab</li><li>• Faricimab</li></ul>
<b>Outcomes</b>	<p>The outcome measures to be considered include:</p> <ul style="list-style-type: none"><li>• visual acuity (the affected eye)</li><li>• overall visual function</li><li>• central subfield foveal thickness (CSFT)</li><li>• adverse effects of treatment (including rate and severity of surgical complications)</li><li>• health-related quality of life.</li></ul>
<b>Economic analysis</b>	<p>The reference case stipulates that the cost effectiveness of treatments should be expressed in terms of incremental cost per quality-adjusted life year.</p> <p>The reference case stipulates that the time horizon for estimating clinical and cost effectiveness should be sufficiently long to reflect any differences in costs or outcomes between the technologies being compared.</p> <p>Costs will be considered from an NHS and Personal Social Services perspective.</p> <p>The availability of any commercial arrangements for the intervention, comparator and subsequent treatment technologies will be taken into account. The availability and cost of biosimilar and generic products should be taken into account.</p> <p>Cost effectiveness analysis should include consideration of the benefit in the best and worst seeing eye.</p>

<b>Other considerations</b>	<p>Guidance will only be issued in accordance with the marketing authorisation. Where the wording of the therapeutic indication does not include specific treatment combinations, guidance will be issued only in the context of the evidence that has underpinned the marketing authorisation granted by the regulator.</p>
<b>Related NICE recommendations and NICE Pathways</b>	<p><b>Related Technology Appraisals:</b></p> <p><a href="#">Ranibizumab and pegaptanib for the treatment of age-related macular degeneration</a> (2008). Last updated 2024. NICE technology appraisal guidance 155.</p> <p><a href="#">Aflibercept solution for injection for treating wet age-related macular degeneration</a> (2013). NICE technology appraisal guidance 294.</p> <p><a href="#">Brolucizumab for treating wet age-related macular degeneration</a> (2021). NICE technology appraisal guidance 294.</p> <p><a href="#">Faricimab for treating wet age-related macular degeneration</a> (2022). NICE technology appraisal guidance 800.</p> <p><a href="#">Bevacizumab gamma for treating wet age-related macular degeneration</a> (2024). NICE technology appraisal guidance 1022.</p> <p><b>Related Guidelines:</b></p> <p><a href="#">Age-related macular degeneration</a> (2018). NICE guideline 82.</p> <p><b>Related Interventional Procedures:</b></p> <p><a href="#">Miniature lens system implantation for advanced age-related macular degeneration</a> (2016). NICE interventional procedures guidance 565.</p> <p><a href="#">Epiretinal brachytherapy for wet age-related macular degeneration</a> (2011). NICE interventional procedures guidance 415.</p> <p><a href="#">Macular translocation with 360° retinotomy for wet age-related macular degeneration</a> (2010). NICE interventional procedures guidance 340.</p> <p><a href="#">Limited macular translocation for wet age-related macular degeneration</a> (2010). NICE interventional procedures guidance 339.</p> <p><a href="#">Transpupillary thermotherapy for age-related macular degeneration</a> (2004). NICE interventional procedures guidance 58.</p> <p><a href="#">Radiotherapy for age-related macular degeneration</a> (2004). NICE interventional procedures guidance 49.</p> <p><b>Related Quality Standards:</b></p> <p><a href="#">Serious eye disorders</a> (2019). NICE quality standard 180.</p>

### References

1. Patient Info (2021). [Age-related Macular Degeneration](#). Accessed January 2026.
2. Owen, C.G., Jarrar, Z., Wormald, R., Cook, D.G., Fletcher, A.E. and Rudnicka, A.R. [The estimated prevalence and incidence of late stage age related macular degeneration in the UK](#). British Journal of Ophthalmology, 2012, 96: 752-756